Boehringer Ingelheim merges AMAL and ViraTherapeutics cancer units, Dantari sells assets to Adanate, Madrona raises $770M, and Abdera adds JJDC and Foresite as investors.

A new report from Novotech reveals the OV market is expanding at pace, with a compounding annual growth rate of 14.2% between 2019 and 2024. More than 95% of ongoing trials involving oncolytic viruses ...

Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech and small to ...

CET – (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced that its management team will participate in the ...

Scientists in China have developed a modified virus that causes cancer cells to make sugars normally found in pigs, causing ...

The confirmatory IGNYTE-3 trial is assessing RP1 in combination with nivolumab in patients with advanced melanoma who have progressed on anti-PD-1 and anti-CTLA-4 therapies or are ineligible for ...

As our knowledge of science and the human body expands, so too do doctors have more tools at hand when treating cancer. One ...